Email UpdatesDescription: This webinar from Serious Mental Illness (SMI) Advisors will provide the latest information on lithium, focusing on new insights into the use of lithium during pregnancy and breastfeeding, and lithium's renal related risks. Important points of emphasis will include the modest effects of lithium on renal function when dosed once daily and 12h outpatient levels are maintained in recommended range of 0.60 - 0.80 mEq/l, and never > 1.00 mEq/l. Attendees will also learn about the importance of the epithelial sodium channel (ENaC), how lithium enters ENaC on distal tubule prinicipal cells and induces polyuria, and why this is the harbinger of renal related adverse effects. Importantly, attendees will be provided modern methods for polyuria monitoring (e.g. Early Morning Urine Osmolality) and its treatment with amiloride, and occasionally adjunctive acetazolamide. As use of VPA has fallen out of favor in the use and has been banned in women of reproductive potential in Western Europe and the UK, clinicians must become adept at using lithium for patients with a history of mania.
Format: Live interactive webinar
Learning Objectives:
- Describe the evidence supporting lithium utilization in patients with bipolar spectrum disorder.
- Implement outpatient 12h trough serum lithium levels and once daily dosing to decrease renal impact.
- Describe the management of common nonrenal adverse effects.
- Evaluate recent findings on lithium use in pregnancy and during breastfeeding.
Target Audience: Psychiatrist, Physician (Non-psychiatrist), Physician Assistant, Psychiatrist, Nurse/Nurse Practitioner, Pharmacist